Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.

Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check out why INO stock is a buy.

It's been an up-and-down year for Inovio Pharmaceuticals (NASDAQ: INO). Shares were up nearly 70% in June before surrendering the gains. The clinical-stage biotech announced its third-quarter results ...

Shares of Inovio Pharmaceuticals Inc. INO advanced 3.31% to $1.56 Thursday, on what proved to be an all-around positive ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat ...

The market expects Inovio Pharmaceuticals (INO) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus ...

Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.31 per share a year ago. These ...

Shares of Inovio Pharmaceuticals Inc. INO shed 3.21% to $1.51 Friday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 0.28% ...